Robert E. Dudley, Ph.D., has served as our Chief Executive Officer, President and Chairman of our board of directors since Clarus's inception in February 2004. Prior to that, from 2001 to 2003, he served as President, Chief Executive Officer, and Director of Anagen Therapeutics, Inc., a private biopharmaceutical company affiliated with the University of Chicago. He served as President, Chief Executive Officer, and Director of Unimed Pharmaceuticals, Inc. from 1999 to 2001 during which time Unimed received FDA approval for and launched AndroGel (which he co-invented). From 1994 to 2001, Dr. Dudley held several senior level executive positions at Unimed Pharmaceuticals, Inc., a public company acquired by Solvay Pharmaceuticals in 1999. Dr. Dudley has over 25 years of experience in the field of testosterone replacement therapy, has published numerous articles in peer-reviewed medical journals, and is an inventor on several testosterone-related patents – including those patents that cover Clarus' oral TU formulations.
Dr. Dudley received his B.S. in Biology from Pepperdine University, Seaver College, his M.S. in Biology from University of New Mexico, and his Ph.D., with honors, in Pharmacology and Toxicology from the University of Kansas School of Medicine. Dr. Dudley is also a board-certified toxicologist.
Steven A. Bourne, CPA, served as our Chief Financial Officer, Secretary and Treasurer since February 2004. He has more than 25 years of experience providing financial leadership for privately held and publicly traded specialty pharmaceutical, biotech and medical device companies. Prior to Clarus, from 2002 to 2003, he served as Chief Financial Officer, Secretary and Treasurer at Anagen Therapeutics, Inc., a private biopharmaceutical company. He served as Controller, Secretary and Treasurer of Aksys, Ltd., a public medical device company from 1996 to 2001. Mr. Bourne received his B.S. in Accounting from Miami University and is a Certified Public Accountant.
Theodore M. Danoff, M.D., Ph.D., received his medical and graduate degrees from the University of Chicago School of Medicine where he was in the Medical Scientist Training Program. Subsequently, he completed his clinical training at the University of Pennsylvania and served on the School of Medicine faculty. Since joining the pharmaceutical industry over 16 years ago, he has designed and run numerous Phase 1-4 clinical trials. Dr. Danoff worked at GlaxoSmithKline (formerly SmithKline Beecham) and, most recently, Endo Pharmaceuticals where he was Vice President, Clinical Development and Medical Affairs. In this capacity, Dr. Danoff played a pivotal role in the approval for Fortesta® (a topical testosterone (T) gel) and Aveed® (a long-acting injectable T product). He also played an important role in the launch of Fortesta.